Dark

Check out our Level2View

FMTX
Forma Therapeutics Holdings, Inc. Common Stock
stock NASDAQ

Inactive

Oct 13, 2022

20.01USD+0.150%(+0.03)739,166

Pre-market

0.00USD-100.000%(-19.98)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 13, 2022

07:05AM EST Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee Business Wire

Jan 7, 2022

07:05AM EST Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 16, 2021

07:08AM EST Forma Therapeutics Announced Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia at ASH 2021 Benzinga

07:05AM EST Forma Therapeutics' Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia Business Wire

Dec 13, 2021

11:54AM EST Forma Therapeutics Early Saturday Announced 'Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease' Benzinga

Dec 11, 2021

11:02AM EST Forma Therapeutics Holdings Inc. (FMTX) said that its investigational oral, once-daily, selective pyruvate kinase-R or PKR activator, etavopivat, significantly improved anemia and red blood cell or RBC health with a favorable tolerability and safety profile in patients with Sickle Cell Disease. RTTNews

09:30AM EST Forma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease Business Wire

Dec 9, 2021

07:05AM EST Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease Business Wire

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 30, 2021

07:05AM EST Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer Business Wire

Nov 19, 2021

08:00AM EST Bolt Biotherapeutics Announces Changes to its Board of Directors GlobeNewswire Inc

Nov 12, 2021

01:09PM EST SVB Leerink Maintains Outperform on Forma Therapeutics Hldgs, Lowers Price Target to $40 Benzinga

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

07:15AM EST Forma Therapeutics Hldgs Q3 EPS $(0.91) Beats $(0.96) Estimate Benzinga

07:08AM EST Forma Therapeutics Q3 Net Loss Widens To $43.3 Mln From $27.6 Mln Last Year RTTNews

07:05AM EST Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Business Wire

04:26AM EST Earnings Scheduled For November 12, 2021 Benzinga

Nov 5, 2021

07:05AM EDT Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021 Business Wire

Nov 4, 2021

09:05AM EDT Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting Business Wire

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 7, 2021

10:49AM EDT 'Re: $FMTX today, there's a precedent for an experimental cancer drug being linked to potential diabetes risk. Who remembers $CLVS, roci and the 2014 ASCO meeting...' -Tweet From STAT News' Adam Feuerstein Benzinga

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

07:19AM EDT Forma Therapeutics Reports Positive Initial Results From Phase 1 Trial Of Oral Small Molecule FT-7051 In Men With MCRPC RTTNews

07:07AM EDT Forma Therapeutics' FT-7051 Is Well-tolerated And Demonstrates Evidence If Activity In Initial Results From Ongoing Phase 1 Courage Study In Men With Metastatic Castration-resistant Prostate Cancer Benzinga

Oct 3, 2021

02:21PM EDT The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More Benzinga

Sep 17, 2021

07:05AM EDT Forma Therapeutics to Participate in Upcoming Investor Conferences Business Wire

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

06:27AM EDT HC Wainwright & Co. Maintains Buy on Forma Therapeutics Hldgs, Lowers Price Target to $53 Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

07:11AM EDT Forma Therapeutics Q2 Net Loss $43.6 Mln Vs $25.4 Mln Last Year RTTNews

07:10AM EDT Forma Therapeutics Hldgs Q2 EPS $(0.92) Misses $(0.79) Estimate Benzinga

07:05AM EDT Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire

04:12AM EDT Earnings Scheduled For August 13, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 6, 2021

07:05AM EDT Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021 Business Wire

Aug 2, 2021

10:23AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2021 Benzinga

09:04AM EDT Craig-Hallum Initiates Coverage On Forma Therapeutics Hldgs with Buy Rating, Announces Price Target of $58 Benzinga

Jun 14, 2021

07:09AM EDT Forma Therapeutics Appoints John Bishop As SVP And Chief Technology Officer RTTNews

07:05AM EDT Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer Business Wire

Jun 11, 2021

02:13PM EDT Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease Benzinga

12:03PM EDT SVB Leerink Maintains Outperform on Forma Therapeutics Hldgs, Lowers Price Target to $54 Benzinga

07:12AM EDT Forma Therapeutics Presents New Phase 1 Data On Etavopivat At EHA Congress RTTNews

07:05AM EDT Forma Therapeutics Highlights Presentation Of New Phase 1 Data On Etavopivat At European Hematology Association Congress Benzinga

07:05AM EDT Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress Business Wire

May 20, 2021

07:07AM EDT Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021 Benzinga

May 17, 2021

07:05AM EDT Forma Therapeutics to Participate in Upcoming Investor Conferences Business Wire

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

07:23AM EDT Forma Therapeutics Q1 Net Loss $36.0 Mln Vs Net Income $11.2 Mln Last Year RTTNews

07:05AM EDT Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Business Wire

04:03AM EDT Earnings Scheduled For May 14, 2021 Benzinga

Mar 31, 2021

08:01AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

06:25AM EDT HC Wainwright & Co. Maintains Buy on Forma Therapeutics Hldgs, Raises Price Target to $55 Benzinga

Mar 30, 2021

11:08AM EDT Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study Benzinga

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

07:30AM EDT Forma Therapeutics Q4 Net Loss $28.6 Mln Vs Loss $24.7 Mln Last Year RTTNews

07:21AM EDT Forma Therapeutics Hldgs Q4 EPS $(0.68) Beats $(0.80) Estimate Benzinga

07:20AM EDT Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update Business Wire

07:14AM EDT Forma Therapeutics Announces FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting Doses Being Evaluated In Phase 2/3 Registrational Trial, Called The Hibiscus Study Benzinga

07:08AM EDT Forma Therapeutics Reports New Data From Phase 1 Trial Of FT-4202 In Patients With Sickle Cell Disease RTTNews

07:05AM EDT Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study Business Wire

04:04AM EDT Earnings Scheduled For March 30, 2021 Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 23, 2021

04:05PM EDT Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021 Business Wire

Feb 17, 2021

07:10AM EST Forma Therapeutics to Participate in Upcoming Investor Conferences Business Wire

Jan 20, 2021

07:08AM EST Forma Therapeutics Announces First Patient Dosed In Phase 1 Clinical Trial Of FT-7051 For MCRPC RTTNews

07:07AM EST Forma Therapeutics Announces First Patient Dosed In Phase 1 Clinical Trial Evaluating FT-7051 For Treatment Of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Benzinga

Jan 11, 2021

07:17AM EST Forma Therapeutics Outlines Key 2021 Milestones RTTNews

07:16AM EST Format Therapeutics Provides 2021 Priorities Benzinga

07:05AM EST Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones Business Wire

Jan 7, 2021

07:15AM EST Forma Therapeutics Elects Selwyn Vickers To Board Of Directos RTTNews

07:05AM EST Forma Therapeutics Elects Renowned Doctor and Health Disparities Expert Selwyn M. Vickers, M.D., to Board of Directors Business Wire

Dec 15, 2020

04:35PM EST Forma Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares Business Wire

Dec 10, 2020

11:05PM EST Forma Therapeutics Prices Underwritten Public Offering Of 5.30 Mln Shares At $45.25/shr RTTNews

10:53PM EST Forma Therapeutics Announces Pricing of Public Offering Business Wire

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 8, 2020

04:15PM EST Forma Therapeutics Launches Proposed Public Offering Business Wire

04:15PM EST Forma Therapeutics Reports 4.6M Share Common Stock Offering Benzinga

09:57AM EST Credit Suisse Maintains Outperform on Forma Therapeutics Hldgs, Raises Price Target to $68 Benzinga

08:15AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

07:02AM EST SVB Leerink Maintains Outperform on Forma Therapeutics Hldgs, Raises Price Target to $65 Benzinga

Dec 7, 2020

04:35PM EST Forma Therapeutics Reports Presentation Of Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD) Benzinga

04:30PM EST Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD) Business Wire

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Nov 19, 2020

09:41AM EST Benzinga's Top Upgrades, Downgrades For November 19, 2020 Benzinga

05:58AM EST Cantor Fitzgerald Initiates Coverage On Forma Therapeutics Hldgs with Overweight Rating, Announces Price Target of $61 Benzinga

Nov 12, 2020

07:28AM EST Forma Therapeutics Q3 Net Loss $27.6 Mln Vs $31.0 Mln Last Year RTTNews

07:16AM EST Forma Therapeutics Q3 Net Loss $27.6M Benzinga

07:05AM EST Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire

Nov 10, 2020

07:05AM EST Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease Business Wire

Nov 4, 2020

01:13PM EST Forma Therapeutics Announces One Oral Presentation, Three Poster Presentations On FT-4202 In Sickle Cell Disease At Upcoming 2020 ASH Virtual Annual Meeting Benzinga

01:11PM EST Forma Therapeutics Announces Four Oral and Poster Presentations on FT-4202 in Sickle Cell Disease at Upcoming 2020 ASH Virtual Annual Meeting Business Wire

07:05AM EST Forma Therapeutics to Participate in Upcoming Investor Conferences Business Wire

Oct 26, 2020

07:14AM EDT Forma Therapeutics Announces Top-Line Olutasidenib Data From Planned Interim Analysis Of Registrational Phase 2 Clinical Trial In Acute Myeloid Leukemia Benzinga

07:12AM EDT Forma Therapeutics Announces Positive Top-line Olutasidenib Data From Interim Analysis Of Registrational Phase 2 Trial RTTNews

07:05AM EDT Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML) Business Wire

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Sep 15, 2020

07:05AM EDT Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions Business Wire

Sep 9, 2020

07:05AM EDT Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors Business Wire

Sep 8, 2020

10:10AM EDT Benzinga's Top Upgrades, Downgrades For September 8, 2020 Benzinga

07:06AM EDT HC Wainwright & Co. Initiates Coverage On Forma Therapeutics Hldgs with Buy Rating, Announces Price Target of $53 Benzinga

Aug 14, 2020

08:26AM EDT The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga

Aug 13, 2020

07:13AM EDT Forma Therapeutics Hldgs Q2 EPS $(4.58) Benzinga

07:11AM EDT Forma Therapeutics Q2 Net Loss $25.4 Mln RTTNews

07:05AM EDT Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire

Jul 30, 2020

07:05AM EDT Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors Business Wire

Jul 14, 2020

09:57AM EDT Benzinga's Top Upgrades, Downgrades For July 14, 2020 Benzinga

06:17AM EDT SVB Leerink Initiates Coverage On Forma Therapeutics Hldgs with Outperform Rating, Announces Price Target of $54 Benzinga

05:41AM EDT Jefferies Initiates Coverage On Forma Therapeutics Hldgs with Buy Rating, Announces Price Target of $54 Benzinga

05:30AM EDT Credit Suisse Initiates Coverage On Forma Therapeutics Hldgs with Outperform Rating, Announces Price Target of $64 Benzinga

Share